Inverness Medical Innovations
6
0
0
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
33.3%
2 terminated/withdrawn out of 6 trials
60.0%
-26.5% vs industry average
0%
0 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts
Role: collaborator
Heart Failure (HF) Assessment With B-type Natriuretic Peptide (BNP) In The Home
Role: collaborator
Neutrophile Gelatinase Associated Lipocalin Evaluation in Septic Acute Kidney Injury
Role: collaborator
The Ischemia Modified Albumin In Diagnosing Ischemic New Events
Role: lead
Clinical Sensitivity of Clearview Rapid Tests in 12-17 y/o Pediatric Population
Role: collaborator
The Utility of Ischemia Modified Albumin (IMA) in Sepsis
Role: lead
All 6 trials loaded